Skip to main content
v2026.11,986 entries · CC-BY 4.0

Editorial · CASRAI · Clinical research and clinical trials

NIH files consultation on wider research safety monitoring

NIH has filed a formal consultation on broader clinical research safety monitoring, with comments due January 6, 2027.

Published 17 Nov 2026· 5 minute read

Ask CASRAI · free to try

Ask about this story

2 free questions a day, no account.

An AI assistant for research: funder rules, compliance, methods and publishing. It links the sources behind its answers and labels answers that come from a web search.

Answers draw on CASRAI's guides and dictionary plus the federal and funder documents we index: Federal Register, Grants.gov, Regulations.gov and UKRI.

Works on this site and inside Claude, Cursor and the AI tools you already use.

Everything CASRAI publishes — this page, the dictionary, the guides and the news — stays open to read, with no account and no card.

CASRAI is the reference for research administration — bookmark it for the next question.

The National Institutes of Health filed a formal Federal Register consultation on November 16, 2026, seeking comments by January 6, 2027, on expanding data and safety monitoring to all NIH-supported clinical research. The proposal would bring more university studies into a risk-based oversight framework, making its scope and approval requirements consequential for investigators and research offices.

New filing follows NIH’s November 2 draft

Federal Register document 2026-23300 was filed at 8:45 a.m. on November 16 and is scheduled for publication on November 17. It contains the draft policy and a request for information, with a written-comment deadline of January 6. The notice is dated November 10 and signed by NIH Principal Deputy Director Matthew J. Memoli.

The filing follows the agency’s November 2 release of NOT-OD-27-006. The newly filed formal notice advances that consultation; it does not adopt the draft or make its proposed requirements effective. NIH is asking whether the approach appropriately protects participants and data integrity, and what guidance would help institutions implement it without unnecessary burden.

Monitoring would extend beyond clinical trials

The central change is coverage. NIH proposes expanding expectations established for clinical trials to all NIH-supported clinical research. The draft’s definition includes patient-oriented research, epidemiological and behavioral studies, and outcomes and health services research. NIH says almost two thirds of its clinical research portfolio consists of studies that are not clinical trials, whose data can support later trial research.

Risk assessment would shape each data and safety monitoring plan. The draft treats risk broadly: participant safety, privacy and confidentiality; data quality and integrity; study complexity and systems; NIH financial stewardship; and other significant concerns, including data security. Assessment could be revisited as a study progresses, rather than treated solely as a decision made at startup.

Under the proposed text, plans would identify critical risks and explain the monitoring methods, evaluation criteria, responses to problems, and documentation. They would also describe reasons for temporary suspension or premature discontinuation and how monitoring reports would be communicated and reviewed. The awarding NIH Institute, Center or Office, collectively termed an ICO, would approve the initial plan before human subject activities begin.

Independent oversight would turn on study risk

NIH describes another change as removing the requirement for Data and Safety Monitoring Boards for all phase 3 or multi-site clinical trials. The replacement would be a study-specific assessment of whether independent monitoring is needed. An independent monitor could be an individual, committee or board, with expertise, responsibilities and independence defined in the plan.

The draft retains investigator monitoring in every study. Independent monitoring would supplement that work where risk warrants it, and the ICO would have to identify its reason for requiring it in writing. NIH says independence can add expertise, reduce bias and protect against conflicts of interest or undue influence.

Risk-proportionate monitoring itself has a long history. The June 10, 1998 NIH policy already linked monitoring to a trial’s risks, size and complexity. The current proposal would broaden the research covered and recast the independent-monitoring decision around each study’s risk assessment.

Earlier sector and campus analysis flags wider reach

In analysis published on November 9, before the Federal Register filing, CITI Program highlighted the implications for institutions conducting research beyond clinical trials. It described responsibilities for developing plans, assessing risks, responding to findings and updating oversight, and suggested involving research administration, human research protections, clinical operations and compliance teams in reviewing the draft.

Harvard Medical School’s existing research-compliance alert likewise draws attention to broader clinical-research coverage, risk-tailored NIH-approved plans and removal of the blanket board requirement. It identifies the January 6 comment deadline and the proposed six-month interval between final policy publication and the application dates covered. These are existing assessments of the draft, rather than new reactions to the November 16 filing.

University workflows would have to connect distinct roles

If finalized as drafted, the policy would make plan approval a study-startup consideration for covered non-trial research as well as trials. For research offices, the practical implication would be connecting application preparation, illustrated in CASRAI’s NIH human-subjects section example, with the proposed monitoring-plan review and approval process before human subject activities start.

The draft leaves the recipient institution responsible for research conduct, even when investigators carry out specified duties. NIH ICO oversight would remain distinct from monitoring performed by investigators, sponsors or independent monitors. Investigators would also have to follow applicable Institutional Review Board requirements. NIH encourages a single monitoring plan that serves NIH, the IRB and other applicable regulators, consistent with Good Clinical Practice.

Oversight would continue throughout the study. The proposed provisions call for at least annual review of routine monitoring reports by people with appropriate expertise, arrangements for expedited reporting when risks trigger escalation, and plan amendments when protocols or risks change. Monitoring costs, including staff time and independent-monitor compensation, could be allowable within study budgets under the draft.

Comments due January 6, with implementation tied to a final policy

The formal request seeks views on calibrating oversight to risk, deciding when independent monitoring adds value, and determining what data-quality issues should be monitored. NIH also invites input on supporting tools, templates, example plans and guidance for different study designs. Responses are voluntary and may be anonymous; NIH warns that submissions may later be made public without redaction.

The immediate opportunity is to comment through the process linked in NIH’s notice by January 6, 2027. Under the draft timetable, the policy would apply to applications submitted on or after six months following publication of a final policy. Its proposed scope lists competing award applications, competitive revisions, contract proposals and other funding agreements, as well as IRB-approved intramural projects. That application timetable is conditional on finalization.

Sources

Referenced across the research world

University of Cambridge logoColumbia University logoCrossref logoUniversity of Edinburgh logoHarvard University logoUniversity of Oxford logoPrinceton University logoStanford School of Medicine logoUniversity College London logoORCID logoUniversity of Cambridge logoColumbia University logoCrossref logoUniversity of Edinburgh logoHarvard University logoUniversity of Oxford logoPrinceton University logoStanford School of Medicine logoUniversity College London logoORCID logo
  • University of Cambridge logo
  • Columbia University logo
  • Crossref logo
  • University of Edinburgh logo
  • Harvard University logo
  • University of Oxford logo
  • Princeton University logo
  • Stanford School of Medicine logo
  • University College London logo
  • ORCID logo

View CASRAI adoption →